))
How CRISPR is Revolutionizing the Treatment of Genetic Diseases
Archived series ("Inactive feed" status)
When?
This feed was archived on May 11, 2019 03:50 (
Why? Inactive feed status. Our servers were unable to retrieve a valid podcast feed for a sustained period.
What now? You might be able to find a more up-to-date version using the search function. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.
Manage episode 170748902 series 1302885
Content provided by Clarivate Analytics – Formerly the IP and Science business of Thomson Reuters. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Clarivate Analytics – Formerly the IP and Science business of Thomson Reuters or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
The recent buzz around CRISPR-Cas9, a genome editing tool, has revolved around its potential for treating various genetic diseases, including cancer. Jack Hopwood, Intellectual Property Consultant and Bertrand Sautier, Strategic Account Manager at Clarivate Analytics talk about how research activity around CRISPR is being measured by tracking R&D strategies and patents. You will also hear about the importance of protecting intellectual property to help accelerate the pace of innovation and minimize the risk of running into costly disputes.
8 episodes
Share
